Bristol-Myers Squibb, one of the many companies touting their cancer drugs ahead of the American Society for Clinical Oncology meeting in Orlando, says that its leukaemia drug Sprycel is showing potential as a treatment for prostate cancer.

The company has announced interim results from two Phase II studies of Sprycel (dasatinib) which demonstrate that it may have potential as a treatment for castrate-resistant prostate cancer. In a single-agent study (CA180-085) examining three doses of the drug in CRPC patients, tumour and prostate-specific antigen response plus decreasing bone turnover was similar in patients receiving once-daily or twice-daily Sprycel schedules.

In an add-on study (CA180-086), with the current standard of care docetaxel (CA180-086), the combination was shown to be well tolerated with no drug-drug interactions observed. On the back of these data, B-MS has started a Phase III trial of Sprycel in combination with docetaxel.

Sprycel, which had sales of $88 million in the first quarter, is currently approved for treating adults with resistance or intolerance to prior therapy for chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia.